No information is available on the clinical use of sitagliptin during breastfeeding. Sitagliptin has a shorter half-life than most other dipeptidyl-peptidase IV inhibitors, so it might be a better choice among drugs in this class for nursing mothers. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with sitagliptin.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
关于西他列汀在母乳喂养期间的临床应用尚无可用信息。西他列汀的半衰期比大多数其他二肽基肽酶IV抑制剂短，因此对于哺乳期母亲来说，它可能是这类药物中的更好选择。在母亲使用西他列汀治疗期间，建议监测母乳喂养婴儿的血糖。[1] 然而，可能更倾向于选择替代药物，尤其是在哺乳新生儿或早产儿期间。
